<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        58-100-11
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2011
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        NOVOSEVEN 5MG POWDER FOR SOLUTION FOR INJECTION
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        RECOMBINAT DNA COAGULATING FACTOR Vlla EPTACOG Alfa ACTIVATED
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder and solvent for solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        3
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        15842.65
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="NOVO NORDISK" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            NOVO NORDISK
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 530]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Salehiya Trading Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            NOVO NORDISK
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        B02BD08 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>NovoSeven<sup>&reg;</sup> is a blood coagulation factor.</strong> It works by making the blood clot at the site of bleeding, when the body&#39;s own clotting factors are not working.</p><p>&nbsp;</p><p><strong>NovoSeven<sup>&reg;</sup> is used </strong>to treat bleeding and to prevent excessive bleeding after surgery or other important treatments. Early treatment with NovoSeven<sup>&reg;</sup> reduces how much you bleed and for how long. It works in all types of bleeds, including joint bleeds. This reduces the need for hospitalisation and days absent from work and school.</p><p>It is used in certain groups of people:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you were <strong><em>born with haemophilia</em></strong> and do not respond normally to factors VIII or IX treatment</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have<strong> <em>acquired haemophilia</em></strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have<strong> <em>factor VII deficiency</em></strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have<strong> <em>Glanzmann&rsquo;s thrombasthenia</em> </strong>(a bleeding disorder) and your condition cannot be treated effectively with platelet transfusion, or if platelets are not readily available.</p><p>&nbsp;</p><p><u>NovoSeven</u><strong><u><sup>&reg;</sup></u></strong><u> can also be given to you by a doctor to treat heavy bleeding after delivery of your baby, even if you do not have a bleeding disorder.</u></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use NovoSeven<sup>&reg;</sup></strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are <strong>allergic to eptacog alfa </strong>(active compound of NovoSeven<sup>&reg;</sup>) or any of the other ingredients in this medicine (listed in section 6)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are<strong> allergic to mouse, hamster</strong> or <strong>cow proteins</strong> (such as cow&rsquo;s milk).</p><p>&nbsp;</p><p>►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If any of these apply to you, <strong>do not use </strong><strong>NovoSeven<sup>&reg;</sup>. Talk to your doctor.</strong></p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>Before treatment with NovoSeven<sup>&reg;</sup>, make sure your doctor knows:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have just had<strong> surgery</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you recently had a<strong> crush injury</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If your<strong> arteries are narrowed</strong> by disease (atherosclerosis)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have an increased risk of <strong>blood clots</strong> (thrombosis)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have severe <strong>liver disease</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have a serious <strong>blood infection</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are prone to <strong><em>disseminated intravascular coagulation</em></strong> (DIC, a condition where blood clots develop throughout the blood stream) you must be carefully monitored.</p><p>&nbsp;</p><p>►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If any of these conditions apply to you, <strong>talk to your doctor before using the injection.</strong></p><p>&nbsp;</p><p><strong>Other medicines and NovoSeven<sup>&reg;</sup></strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>&nbsp;</p><p>Do not use NovoSeven<sup>&reg;</sup> at the same time as <em>prothrombin complex concentrates </em>or rFXIII.</p><p>You should talk to your doctor before using NovoSeven<sup>&reg;</sup> if you also use factor VIII or IX products.</p><p>&nbsp;</p><p>There is limited experience of using NovoSeven<sup>&reg;</sup> together with medicines called <em>antifibrinolytic drugs </em>(such as aminocaproic acid or tranexamic acid) which are also used to control bleeding. You should talk to your doctor before using NovoSeven<sup>&reg;</sup> with these medicines.</p><p>&nbsp;</p><p><strong>Pregnancy, breast-feeding and fertility</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before you use NovoSeven<sup>&reg;</sup>.</p><p>&nbsp;</p><p><strong>Driving and using machines </strong></p><p>There are no studies on the effect of NovoSeven<sup>&reg;</sup> on the ability to drive and use machines. However, there is no medical reason to think that it would affect your ability.</p><p>&nbsp;</p><p><strong><u>NovoSeven<sup>&reg;</sup> contains sodium</u></strong></p><p><u>This medicine contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per injection, i.e. essentially &lsquo;sodium-free&rsquo;.</u></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>The NovoSeven<sup>&reg;</sup> powder must be reconstituted with its solvent</strong> and injected into a vein. See overleaf for detailed instructions.</p><p>&nbsp;</p><p><strong>When to treat yourself</strong></p><p><strong>Start treatment of a bleed as early as possible,</strong> ideally within 2 hours.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>In cases of a mild or moderate bleed,</strong> you should treat yourself as early as possible, ideally at home.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>In case of a severe bleed,</strong> you should contact your doctor. Usually severe bleeds are treated at the hospital, and you can give yourself the first NovoSeven<sup>&reg;</sup> dose on the way there.</p><p>&nbsp;</p><p>Do not treat yourself for longer than 24 hours without consulting your doctor.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Each time you use NovoSeven<sup>&reg;</sup>, <strong>tell your doctor or hospital as soon as possible.</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If bleeding is not controlled within 24 hours, <strong>contact your doctor immediately. You will usually need hospital care.</strong></p><p>&nbsp;</p><p><strong>Dose</strong></p><p><strong>The first dose should be given as early as possible </strong>after bleeding has started. Talk to your doctor about when to use the injections and how long to keep using them.</p><p>The dose will be worked out by your doctor, based on your body weight, condition and type of bleed.</p><p>To achieve the best results, follow the prescribed dose carefully. Your doctor might change the dose.</p><p>&nbsp;</p><p><strong><em>If you have haemophilia</em></strong></p><p>The usual dose is 90 micrograms for every 1 kilogram you weigh; you can repeat the injection every 2&ndash;3 hours until bleeding is controlled.</p><p>Your doctor may recommend a single dose of 270 micrograms for every 1 kilogram you weigh. There is no clinical experience in people over 65 using this single dose.</p><p>&nbsp;</p><p><strong><em>If you have factor VII deficiency</em></strong></p><p>The usual dose range<strong> </strong>is 15 to 30 micrograms for every 1 kilogram you weigh, for each injection.</p><p>&nbsp;</p><p><strong><em>If you have Glanzmann&rsquo;s thrombasthenia</em></strong></p><p>The usual dose is 90 micrograms<strong> </strong>(range is 80 to 120 micrograms) for every 1 kilogram you weigh, for each injection.</p><p>&nbsp;</p><p><strong>If you inject more NovoSeven<sup>&reg;</sup> than you should</strong></p><p>If you inject too much NovoSeven<sup>&reg;</sup>, get medical advice at once.</p><p>&nbsp;</p><p><strong>If you forget an injection of NovoSeven<sup>&reg;</sup></strong></p><p>If you forget an injection, or if you want to stop the treatment, get your doctor&rsquo;s advice.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>Serious side effects</strong></p><p>Rare<em> (may affect up to 1 in 1,000 treatment episodes)</em></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Allergic, hypersensitivity or anaphylactic reactions. Signs may include skin rashes, itching, flushing and hives; wheezing or difficulty breathing; feeling faint or dizzy; and severe swelling of the lips or throat, or at the injection site.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blood clots in arteries in the heart (which could lead to a heart attack or angina), in the brain (which could lead to a stroke) or in the intestine and kidneys. Signs may include severe pain in the chest, breathlessness, confusion, difficulty with speech or movement (paralysis) or abdominal pain.</p><p>&nbsp;</p><p>Uncommon<em> (may affect up to 1 in 100 treatment episodes)</em></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blood clots in the veins in lungs, legs, liver, kidneys or at the injection site. Signs may include difficulty in breathing, red and painful swelling in the leg and abdominal pain.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lack of effect or decreased response to treatment.</p><p>&nbsp;</p><p>►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you notice any of these serious side effects,</strong> <strong>get medical help immediately.</strong> Explain that you have been using NovoSeven<sup>&reg;</sup>.</p><p>&nbsp;</p><p>Remind your doctor <strong>if you have a history of allergic reactions</strong> as you may need to be monitored more carefully. In most cases of blood clots, the patients were predisposed to blood clotting disorders.</p><p>&nbsp;</p><p><strong>Other rare side effects</strong></p><p><em>(may affect up to 1 in 1,000 treatment episodes)</em></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nausea (feeling sick)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Changes in some liver and blood tests.</p><p>&nbsp;</p><p><strong>Other uncommon side effects</strong></p><p><em>(may affect up to 1 in 100 treatment episodes)</em></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Allergic skin reactions including rash, itching and hives</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fever.</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep this medicine out of the sight and reach of children.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use this medicine after the expiry date that is stated on the carton. The expiry date refers to the last day of that month.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store powder and solvent below 25&deg;C.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store powder and solvent protected from light.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not freeze.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Use NovoSeven<sup>&reg;</sup> at once</strong> after mixing the powder with the solvent to avoid infection. If you cannot use it immediately after it has been mixed, you should store it in the vial with the vial adapter and syringe still attached in a refrigerator at 2&deg;C to 8&deg;C for no longer than 24 hours. Do not freeze the mixed NovoSeven<sup>&reg;</sup> solution and keep it protected from light. Do not store the solution without advice from your doctor or nurse.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What NovoSeven<sup>&reg;</sup> contains </strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is recombinant coagulation factor VIIa (activated eptacog alfa).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients in the powder are sodium chloride, calcium chloride dihydrate, glycylglycine, polysorbate 80, mannitol, sucrose, methionine, hydrochloric acid, sodium hydroxide. The ingredients in the solvent are histidine, hydrochloric acid, sodium hydroxide, water for injections.</p><p>&nbsp;</p><p>The powder for solution for injection contains: 1 mg/vial (corresponding to 50 KIU/vial), 2 mg/vial (corresponding to 100 KIU/vial), 5 mg/vial (corresponding to 250 KIU/vial) or 8 mg/vial (corresponding to 400 KIU/vial).</p><p>After reconstitution, 1 ml of the solution contains 1 mg eptacog alfa (activated).</p><p>1 KIU equals 1,000 IU (International Units).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                The powder vial contains white powder, and the pre-filled syringe contains a clear colourless solution. The reconstituted solution is colourless. Do not use the reconstituted solution if you notice particles in it or if it is discoloured. 

Each NovoSeven® pack contains:
•	1 vial with white powder for solution for injection
•	1 vial adapter
•	1 pre-filled syringe with solvent for reconstitution
•	1 plunger rod.

Pack sizes: 1 mg (50 KIU), 2 mg (100 KIU), 5 mg (250 KIU) and 8 mg (400 KIU).
Please refer to outer packaging for present pack size.
Not all pack sizes may be marketed.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Novo Nordisk A/S</p><p>Novo All&eacute;</p><p>DK-2880 Bagsv&aelig;rd, Denmark</p><p>&nbsp;</p><p>To report any side effect(s):</p><p>The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>&bull; Fax: +966-11-205-7662</p><p>&bull; SFDA call centre 19999</p><p>&bull; Toll free phone: 8002490000</p><p>&bull; E-mail: npc.drug@sfda.gov.sa</p><p>&bull; Website: www.sfda.gov.sa/npc</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in APR 2022
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>نوفوسفن</strong><strong><sup>&trade;</sup></strong><strong> عبارة عن عامل تخثر للدم.</strong> ويعمل عن طريق جعل الدم يتخثر في موضع النزف، وذلك عندما يكون هناك خلل في عوامل التخثر الموجودة طبيعياً في الجسم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يتم استخدام</strong> <strong>نوفوسفن</strong><strong><sup>&trade;</sup></strong><strong> </strong>لعلاج<strong> </strong>حالات النزيف ولمنع النزيف شديد أو مفرط بعد الجراحة أو أية علاجات أخرى هامة. إن العلاج المبكر باستخدام دواء نوفوسفن<sup>&trade;</sup> يقلل كمية النزيف ومدته. ويتناسب هذا الدواء مع كل أنواع النزيف، بما فيها نزيف المفاصل. يقلل هذا الدواء من الحاجة إلى التداوي بالمستشفى والتغيب عن العمل والمدرسة.</p><p dir="RTL">يتم استخدام هذا الدواء لمجموعات معينة من الأشخاص:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت <strong><em>مولوداً</em></strong> <strong><em>بمرض الهيموفيليا</em></strong> ولا تستجيب للعلاج بعامل التخثر الثامن أو التاسع</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا<em> <strong>أُصبت</strong></em><strong> <em>بمرض الهيموفيليا المكتسبة.</em></strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من <strong><em>نقص في</em></strong> <strong><em>العامل السابع</em></strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من<strong> <em>داء وهن الصفيحات المنسوب لجلانزمان</em> </strong>(مرض نزفي) ولا يمكن علاج حالتك عن طريق نقل الصفائح الدموية أو في حالة عدم توفر الصفائح الدموية بسهولة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>يمكن أن يعطيك الطبيب نوفوسفن&trade; أيضًا لعلاج النزيف الحاد بعد ولادة طفلك ، حتى لو لم يكن لديك اضطراب نزيف.</u></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&nbsp;لا تستخدم نوفوسفن</strong><strong><sup>&trade;</sup></strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من <strong>حساسية</strong> <strong>من</strong><strong> الإبتاكوج ألفا </strong>( المادة الفعالة لدواء نوفوسفن<sup>&trade;</sup>) أو<strong> </strong>أيٍ من مكونات هذا الدواء (المذكورة في القسم 6)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من <strong>حساسية</strong> <strong>من</strong><strong> الفئران</strong> أو <strong>الجرذ الأرنبي أو</strong> <strong>بروتينات البقر </strong>(مثل اللبن البقري).</p><p dir="RTL">&nbsp;</p><p dir="RTL">►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت أيٌ من هذه الحالات تنطبق عليك، <strong>فلا تستخدم دواء نوفوسفن</strong><strong><sup>&trade;</sup></strong><strong>. ينبغي استشارة الطبيب.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تحذيرات واحتياطات</strong></p><p dir="RTL">قبل العلاج بدواء نوفوسفن<sup>&trade;</sup>، تأكد من أن طبيبك يعلم:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد خضعت<strong> لأية جراحة قريباً</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد أُصبت حديثاً<strong> بإصابة هرسية</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت<strong> الشرايين لديك قد ضاقت</strong> بسبب مرض (تصلب الشرايين)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت معرضاً بشكل زائد لمخاطر <strong>التجلطات الدموية</strong> (التخثر)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصاباً <strong>بمرض كبدي شديد</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابا بعدوي<strong> خطيرة عن طريق الدم</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت معرضاً <strong><em>للتخثر المنتثر داخل الأوعية</em></strong> (DIC، حالة تتطور فيها تخثرات دموية داخل مجرى الدم)، فيجب مراقبة حالتك بشكل دقيق.</p><p dir="RTL">&nbsp;</p><p dir="RTL">►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت أيٌ من الحالات السابقة تنطبق عليك، <strong>فاستشر طبيبك قبل استعمال الحقنة.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأدوية الأخرى ونوفوسفن</strong><strong><sup>&trade;</sup></strong></p><p dir="RTL">أخبر الطبيب أو الصيدلي إذا كنت تتناول أدوية أخرى أو تناولت أي أدوية أخرى مؤخراً أو قد تتناول أدوية أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم نوفوسفن<sup>&trade;</sup> في نفس توقيت استخدام <em>مركزات البروثرومبين المعقدة </em><em>(PCC)</em> أو العامل الثالث عشر المؤتلف (rFXIII).</p><p dir="RTL">يجب استشارة طبيبك قبل استعمال نوفوسفن<sup>&trade;</sup> إذا كنت تستخدم أيضاً منتجات العامل الثامن أو التاسع.</p><p dir="RTL">&nbsp;</p><p dir="RTL">توجد تجارب محدودة حول استخدام نوفوسفن<sup>&trade;</sup> مع أدوية تُسمى <em>الأدوية المضادة &nbsp;لحل الفبرين</em> (مثل حمض الأمينوكابرويك أو حمض الترانيكساميك) والتي يتم استخدامها أيضاً للتحكم في النزيف<strong>. </strong>ينبغي استشارة طبيبك قبل استخدام نوفوسفن<sup>&trade;</sup> مع هذه الأدوية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة والخصوبة</strong></p><p dir="RTL">في حالة الحمل أو الرضاعة الطبيعية، أو إذا كنتِ تظنين أنكِ حامل أو تنوين الحمل، فاستشيري طبيبك قبل استعمال نوفوسفن<sup>&trade;</sup>.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات </strong></p><p dir="RTL">لا توجد دراسات عن تأثير نوفوسفن<sup>&trade;</sup> على القدرة على القيادة واستخدام الآلات. ولكن، لا يوجد سبب طبي للاعتقاد بأن الدواء قد يؤثر على هذه القدرة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><u>نوفوسفن</u></strong><strong><u>&trade; يحتوي على الصوديوم</u></strong></p><p dir="RTL"><u>يحتوي هذا الدواء على أقل من 1 مليمول صوديوم (23 م</u><u>ل</u><u>جم) لكل حقنة، أي بشكل أساسي &quot;خالي من الصوديوم&quot;.</u></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>يجب إذابة مسحوق</strong> <strong>نوفوسفن</strong><strong><sup>&trade;</sup></strong><strong> مع المذيب الخاص به</strong> وحقنه في الوريد. انظر خلف النشرة للاطلاع على التعليمات التفصيلية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>متى يمكنك علاج نفسك</strong></p><p dir="RTL"><strong>قم ببدء علاج النزيف مبكراً بقدر المستطاع</strong>، والأفضل خلال ساعتين.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>في حالات النزيف البسيط أو المتوسط، </strong>يجب علاج نفسك مبكراً بقدر المستطاع، والأفضل العلاج في المنزل.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>في حالة النزيف الشديد،</strong> يجب الاتصال بالطبيب. دائماً ما يتم علاج حالات النزيف الشديدة في المستشفى، ويمكنك إعطاء نفسك أول جرعة من نوفوسفن<sup>&trade;</sup> في طريقك إلى المستشفى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تعالج نفسك لأكثر من 24 ساعة بدون استشارة الطبيب.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في كل مرة تستخدم فيها دواء نوفوسفن<sup>&trade;</sup>، <strong>أخبر الطبيب أو المستشفى في أقرب وقت ممكن.</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حالة عدم السيطرة على النزيف خلال 24 ساعة، <strong>اتصل بطبيبك على الفور. فسوف تحتاج دائماً إلى الرعاية بالمستشفى.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الجرعة</strong></p><p dir="RTL"><strong>يجب إعطاء أول جرعة في أقرب وقت ممكن </strong>بعد بدء النزيف. تحدث إلى طبيبك بشأن متى يجب استخدام الحُقن ومدة المداومة على استخدامها.</p><p dir="RTL">سيتم تحديد الجرعة بواسطة الطبيب، وفقاً لوزن الجسم وحالة النزيف ونوعه.</p><p dir="RTL">لتحقيق أفضل النتائج، اتبع الجرعة الموصوفة بدقة. وقد يقوم طبيبك بتغيير الجرعة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><em>إذا كنت مصاباً بمرض الهيموفيليا</em></strong></p><p dir="RTL">تكون الجرعة المعتادة هي 90 ميكروجرام لكل 1 كيلوجرام من وزنك؛ يمكنك تكرار الحقن كل 2&ndash;3 ساعات حتى تتم السيطرة على النزيف.</p><p dir="RTL">قد يوصي طبيبك بجرعة واحدة مقدارها 270 ميكروجرام لكل كيلوجرام من وزنك. لا توجد تجربة سريرية حول استخدام الأشخاص الأكبر سناً من 65 عاماً لهذه الجرعة الواحدة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><em>إذا كنت تعاني من نقص في العامل السابع</em></strong></p><p dir="RTL">تتراوح الجرعة المعتادة<strong> </strong>من 15 إلى 30 ميكروجرام لكل كيلوجرام من وزنك، لكل حقنة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><em>إذا كنت مصاباً بداء وهن الصفيحات المنسوب لجلانزمان</em></strong></p><p dir="RTL">الجرعة المعتادة هي 90 ميكروجراماً<strong> </strong>(تتراوح من 80 إلى 120 ميكروجراماً) لكل كيلوجرام من وزنك، لكل حقنة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>في حالة الحقن بجرعة زائدة من نوفوسفن</strong><strong><sup>&trade;</sup></strong><strong> عن الجرعة الموصوفة</strong></p><p dir="RTL">في حالة الحقن بجرعة زائدة من نوفوسفن<sup>&trade;</sup>، اطلب المشورة الطبية فوراً.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>في حالة نسيان حقنة من نوفوسفن</strong><strong><sup>&trade;</sup></strong></p><p dir="RTL">في حالة نسيان حقنة، أو إذا كنت تريد إيقاف العلاج، استشر طبيبك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثله مثل جميع الأدوية، يمكن أن يسبب هذا الدواء آثاراً جانبية، ولكن لا يُصاب بها الجميع.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية الخطيرة</strong></p><p dir="RTL">نادرة <em>(قد تصيب حتى حالة واحدة من بين </em><em>1000</em><em> حالة)</em></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات أرجية أو فرط حساسية أو تفاعلات تحسسية شديدة. قد تشمل العلامات ظهور طفح جلدي أو حكة أو بيغ أو شرى؛ وصفير أو شعور بصعوبة في التنفس؛ وشعور بالدوار أو بالإغماء؛ وتورم حاد في الشفاه أو الحلق، أو في موضع الحقن.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جلطات دموية في شرايين القلب (والتي قد تؤدي إلى حدوث سكتة قلبية أو ذبحة صدرية)، أو في المخ (والتي قد تؤدي إلى حدوث جلطة دماغية) أو في الأمعاء والكليتين. وقد تشتمل العلامات على ألم حاد في الصدر أو عسر تنفس أو تشوش أو صعوبة في الكلام أو الحركة (شلل) أو ألم في البطن.</p><p dir="RTL">&nbsp;</p><p dir="RTL">غير شائعة <em>(قد تصيب حتى حالة واحدة من بين </em><em>100</em><em> حالة)</em></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جلطات دموية في أوردة الرئتين أو الساقين أو الكبد أو الكليتين أو في موضع الحقن. وقد تشمل العلامات صعوبة في التنفس وتورم أحمر ومؤلم في الساق وألم في البطن.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص تأثير العلاج أو نقصان الاستجابة للعلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL">►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا لاحظت وجود أي من هذه الآثار الجانبية الخطيرة،</strong> <strong>فاطلب المساعدة الطبية على الفور.</strong> واشرح للطبيب أنك كنت تستخدم دواء نوفوسفن<sup>&trade;</sup>.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قم بتذكير طبيبك <strong>إذا كان لديك تاريخ مرضي من الإصابة بتفاعلات أرجية</strong>، حيث قد يستلزم مراقبة حالتك بعناية. في معظم حالات الجلطات الدموية، كان المرضى قد تعرضوا من قبل لاضطرابات تجلط الدم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آثار جانبية نادرة أخرى</strong></p><p dir="RTL"><em>(قد تصيب حتى حالة واحدة من بين </em><em>1000</em><em> حالة)</em></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الغثيان (التوعك)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات في بعض اختبارات الدم والكبد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آثار جانبية غير شائعة أخرى</strong></p><p dir="RTL"><em>(قد تصيب حتى حالة واحدة من بين </em><em>100</em><em> حالة)</em></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات حساسية جلدية، تشمل الطفح الجلدي والحكة والشرى</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">إذا أُصبت بأيٍ من الآثار الجانبية، فينبغي استشارة الطبيب. يشمل هذا أية آثار جانبية محتملة غير واردة في هذه النشرة. فمن خلال الإبلاغ عن الآثار الجانبية، يمكنك المساعدة في تقديم المزيد من المعلومات حول سلامة هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احفظ هذا الدواء بعيداً عن متناول ومرأى الأطفال.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المدون على العبوة. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من الشهر المذكور.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قم بتخزين المسحوق والمذيب في درجة حرارة أقل من 25 درجة مئوية.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قم بتخزين المسحوق والمذيب بعيداً عن الضوء.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُراعى عدم التجميد.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>استخدم نوفوسفن</strong><strong><sup>&trade;</sup></strong><strong> فور</strong> مزج المسحوق مع المذيب لتجنب حدوث عدوى. وإذا لم تستطع استخدامه مباشرةً بعد المزج، فيجب تخزينه في الثلاجة داخل القنينة مع مهايئ القنينة والاحتفاظ بالحقنة مركبةً، في درجة حرارة من 2 حتى 8 درجات مئوية لمدة لا تتعدى 24 ساعة. لا تقم بتجميد محلول نوفوسفن<sup>&trade;</sup> الذي تم مزجه، واحفظه بعيداً عن الضوء. لا تقم بتخزين المحلول بدون مشورة الطبيب أو الممرض.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تتخلص من أية أدوية في مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي بشأن كيفية التخلص من الأدوية التي لم تعد تستعملها. ستساعد هذه التدابير على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>محتويات دواء نوفوسفن</strong><strong><sup>&trade;</sup></strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة هي عامل التخثر السابع أ المؤتلف (إبتاكوج ألفا النشط).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى الموجودة في المسحوق هي كلوريد الصوديوم وكلوريد الكالسيوم ثنائي الهيدرات وجليسيل الجليسين وبوليسوربات 80 ومانيتول وسكروز وميثيونين وحمض الهيدروكلوريك وهيدروكسيد الصوديوم. بينما تشتمل المكونات الموجودة في المذيب على هيستيدين وحمض الهيدروكلوريك وهيدروكسيد الصوديوم وماء للحقن.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&rlm;‫يحتوي مسحوق المحلول الخاص بالحقن على: 1 ملجم/القنينة (يوافق 50 ألف وحدة دولية/القنينة) أو 2 ملجم/القنينة (يوافق 100 ألف وحدة دولية/القنينة) أو 5 ملجم/القنينة (يوافق 250 ألف وحدة دولية/القنينة) أو 8 ملجم/القنينة (يوافق 400 ألف وحدة دولية/القنينة).</p><p dir="RTL">بعد الإذابة، سوف يحتوي 1 مل من المحلول على 1 ملجم من الإبتاكوج ألفا (النشط).</p><p dir="RTL">وحدة KIU تساوي 1000 وحدة دولية (IU).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="direction:rtl; text-align:right">تحتوي قنينة المسحوق على مسحوق أبيض، وتحتوي الحقنة المعبأة مسبقاً على محلول صافٍ عديم اللون. يكون المحلول المذاب عديم اللون. لا تستخدم المحلول المذاب إذا لاحظت وجود جزيئيات داخله أو إذا تغير لونه.</p><p dir="RTL" style="direction:rtl; text-align:right">&nbsp;</p><p dir="RTL" style="direction:rtl; text-align:right">تحتوي كل عبوة من نوفوسفن<sup>&trade;</sup> على:</p><p dir="RTL" style="direction:rtl; text-align:right">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قنينة واحدة بها مسحوق أبيض لمحلول الحقن</p><p dir="RTL" style="direction:rtl; text-align:right">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مهايئ القنينة</p><p dir="RTL" style="direction:rtl; text-align:right">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حقنة واحدة معبأة مسبقاً تحتوي على مذيب للإذابة</p><p dir="RTL" style="direction:rtl; text-align:right">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ذراع كبّاس واحد.</p><p dir="RTL" style="direction:rtl; text-align:right">&nbsp;</p><p dir="RTL" style="direction:rtl; text-align:right">&rlm;‫أحجام العبوات: 1 ملجم (50 ألف وحدة دولية) و2 ملجم (100 ألف وحدة دولية) و5 ملجم (250 ألف وحدة دولية) و8 ملجم (400 ألف وحدة دولية).</p><p dir="RTL" style="direction:rtl; text-align:right">الرجاء الرجوع إلى العبوة الخارجية للتعرف على حجم العبوة الحالية.</p><p dir="RTL" style="direction:rtl; text-align:right">لا تتوفر جميع أحجام العبوات في بعض الأسواق.</p><p dir="RTL" style="direction:rtl; text-align:right">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">Novo Nordisk A/S</p><p dir="RTL">Novo All&eacute;</p><p dir="RTL">DK-2880 Bagsv&aelig;rd Denmark</p><p dir="RTL">&nbsp;</p><p dir="RTL">للإبلاغ عن أعراض جانبية<br />المركز الوطني للتيقظ والسلامة الدوائية<br />+966-11- &bull; فاكس: 2057662<br />&bull; للاتصال بالمركز الموحد للهيئة العامة للغذاء والدواء 19999<br />&bull; الهاتف المجاني: 8002490000<br />npc.drug@sfda.gov.sa : &bull; بريد الالكتروني<br />www.sfda.gov.sa/npc : &bull; الموقع الالكتروني</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تم مراجعة النشرة في أبريل 2022
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                NovoSeven 5 mg (250 KIU) powder and solvent for solution for injection
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                NovoSeven 5 mg (250 KIU)
NovoSeven is presented as powder and solvent for solution for injection containing 5 mg eptacog alfa (activated) per vial (corresponds to 250 KIU/vial).
1 KIU equals 1,000 IU (International Units).

eptacog alfa (activated) is recombinant coagulation factor VIIa (rFVIIa) with a molecular mass of approximately 50,000 Daltons produced in baby hamster kidney cells (BHK Cells) by recombinant DNA technology.

After reconstitution, the product contains 1 mg/ml eptacog alfa (activated) when reconstituted with solvent.

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder and solvent for solution for injection.

White lyophilised powder. Solvent: clear colourless solution. The reconstituted solution has a pH of approximately 6.0.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>NovoSeven is indicated for the treatment of bleeding episodes and for the prevention of bleeding in those undergoing surgery or invasive procedures in the following patient groups:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in patients with congenital haemophilia with inhibitors to coagulation factors VIII or IX&nbsp;&gt;&nbsp;5&nbsp;Bethesda Units (BU)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in patients with congenital haemophilia who are expected to have a high anamnestic response to factor VIII or factor IX administration</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in patients with acquired haemophilia</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in patients with congenital FVII deficiency</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in patients with Glanzmann&rsquo;s thrombasthenia with past or present refractoriness to platelet transfusions, or where platelets are not readily available.</p><p>&nbsp;</p><p><u>Severe postpartum haemorrhage</u></p><p>NovoSeven is indicated for the treatment of severe postpartum haemorrhage when uterotonics are insufficient to achieve haemostasis.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment should be initiated under the supervision of a physician experienced in the treatment of haemophilia and/or bleeding disorders.</p><p>&nbsp;</p><p>In the management of severe postpartum haemorrhage, appropriate multidisciplinary expertise should be consulted. In addition to obstetricians, this includes anaesthesiologists, critical care specialists and/or haematologists. Standard management practices should remain implemented, based on the individual patient&rsquo;s requirements. Maintenance of adequate fibrinogen concentration and platelet count is recommended in order to optimise the benefit of NovoSeven treatment.</p><p><em><u>&nbsp;</u></em></p><p><strong>Posology</strong></p><p>&nbsp;</p><p><em>Haemophilia A or B with inhibitors or expected to have a high anamnestic response</em></p><p><u>&nbsp;</u></p><p><u>Dose</u></p><p>NovoSeven should be given as early as possible after the start of a bleeding episode. The recommended initial dose, administered by intravenous bolus injection, is 90&nbsp;&mu;g per kg body weight.</p><p>Following the initial dose of NovoSeven further injections may be repeated. The duration of treatment and the interval between injections will vary with the severity of the haemorrhage, the invasive procedures or surgery being performed.</p><p>&nbsp;</p><p><u>Paediatric population </u></p><p>Current clinical experience does not warrant a general differentiation in dosing between children and adults, although children have faster clearance than adults. Therefore, higher doses of rFVIIa may be needed in paediatric patients to achieve similar plasma concentrations as in adult patients (see section 5.2).</p><p><u>&nbsp;</u></p><p><u>Dose interval</u></p><p>Initially 2 &ndash; 3&nbsp;hours to obtain haemostasis.</p><p>If continued therapy is needed, the dose interval can be increased successively once effective haemostasis is achieved to every 4, 6, 8 or 12&nbsp;hours for as long as treatment is judged as being indicated.</p><p>&nbsp;</p><p><u>Mild to moderate bleeding episodes (including home therapy)</u></p><p>Early intervention has been shown to be efficacious in the treatment of mild to moderate joint, muscle and mucocutaneous bleeds. Two dosing regimens can be recommended:</p><p>&nbsp;</p><p>1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Two to three injections of 90&nbsp;&micro;g per kg body weight administered at three-hour intervals.</p><p>If further treatment is required, one additional dose of 90&nbsp;&micro;g per kg body weight can be administered.</p><p>2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; One single injection of 270&nbsp;&micro;g per kg body weight.</p><p>&nbsp;</p><p>The duration of home therapy should not exceed 24&nbsp;hours. Only after consultation with the haemophilia treatment centre can continued home treatment be considered.</p><p>&nbsp;</p><p>There is no clinical experience with administration of a single dose of 270&nbsp;&micro;g per kg body weight in elderly patients.</p><p>&nbsp;</p><p><u>Serious bleeding episodes</u></p><p>An initial dose of 90&nbsp;&micro;g per kg body weight is recommended and could be administered on the way to the hospital where the patient is usually treated. The following dose varies according to the type and severity of the haemorrhage. Dosing frequency should initially be every second hour until clinical improvement is observed. If continued therapy is indicated, the dose interval can then be increased to 3&nbsp;hours for 1 &ndash; 2&nbsp;days. Thereafter, the dose interval can be increased successively to every 4, 6, 8 or 12&nbsp;hours for as long as treatment is judged as being indicated. A major bleeding episode may be treated for 2 &ndash; 3&nbsp;weeks but can be extended beyond this if clinically warranted.</p><p>&nbsp;</p><p><u>Invasive procedure/surgery</u></p><p>An initial dose of 90&nbsp;&micro;g per kg body weight should be given immediately before the intervention. The dose should be repeated after 2&nbsp;hours and then at 2 &ndash; 3&nbsp;hour intervals for the first 24 &ndash; 48&nbsp;hours depending on the intervention performed and the clinical status of the patient. In major surgery, the dose should be continued at 2 &ndash; 4&nbsp;hour intervals for 6 &ndash; 7&nbsp;days. The dose interval may then be increased to 6 &ndash; 8&nbsp;hours for another 2&nbsp;weeks of treatment.</p><p>Patients undergoing major surgery may be treated for up to 2 &ndash; 3&nbsp;weeks until healing has occurred.</p><p><em>&nbsp;</em></p><p><em>Acquired Haemophilia</em></p><p>&nbsp;</p><p><u>Dose and dose interval</u></p><p>NovoSeven should be given as early as possible after the start of a bleeding episode. The recommended initial dose, administered by intravenous bolus injection, is 90&nbsp;&micro;g per kg body weight. Following the initial dose of NovoSeven further injections may be given if required. The duration of treatment and the interval between injections will vary with the severity of the haemorrhage, the invasive procedures or the surgery being performed.</p><p>The initial dose interval should be 2 &ndash; 3&nbsp;hours. Once haemostasis has been achieved, the dose interval can be increased successively to every 4, 6, 8 or 12&nbsp;hours for as long as treatment is judged to be indicated.</p><p>&nbsp;</p><p><em>Factor VII deficiency</em></p><p>&nbsp;</p><p><u>Dose, dose range and dose interval</u></p><p>The recommended dose range in adults and children for treatment of bleeding episodes and for the prevention of bleeding in patients undergoing surgery or invasive procedures is 15 &ndash; 30&nbsp;&mu;g per kg body weight every 4 &ndash; 6&nbsp;hours until haemostasis is achieved. Dose and frequency of injections should be adapted to each individual.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>Limited clinical experience in long term prophylaxis has been gathered in the paediatric population below 12 years of age, with a severe clinical phenotype (see section 5.1).</p><p>&nbsp;</p><p>Dose and frequency of injections for prophylaxis should be based on clinical response and adapted to each individual.</p><p>&nbsp;</p><p><em>Glanzmann&rsquo;s thrombasthenia</em></p><p>&nbsp;</p><p><u>Dose, dose range and dose interval</u></p><p>The recommended dose for treatment of bleeding episodes and for the prevention of bleeding in patients undergoing surgery or invasive procedures is 90&nbsp;&micro;g (range 80 &ndash; 120&nbsp;&micro;g) per kg body weight at intervals of two hours (1.5 &ndash; 2.5&nbsp;hours). At least three doses should be administered to secure effective haemostasis. The recommended route of administration is bolus injection as lack of efficacy may appear in connection with continuous infusion.</p><p>&nbsp;</p><p>For those patients who are not refractory, platelets is the first line treatment for Glanzmann&rsquo;s thrombasthenia.</p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>Severe postpartum haemorrhage</u></em></p><p><em><u>&nbsp;</u></em></p><p><u>Dose range and dose interval</u></p><p><u>The recommended dose range for the treatment of bleeding is 60 &ndash; 90&nbsp;&micro;g per kg body weight administered by intravenous bolus injection. Peak coagulant activity can be expected at 10&nbsp;minutes. A second dose can be administered based on clinical response of the individual patient. </u></p><p><u>It is recommended that in case of insufficient haemostatic response, a second dose can be administered after 30</u><u>&nbsp;</u><u>minutes.</u></p><p>&nbsp;</p><p><strong>Method of administration</strong></p><p>For instructions on reconstitution of the medicinal product before administration, see section 6.6. Administer the solution as an intravenous bolus injection over 2 &ndash; 5&nbsp;minutes.</p><p>&nbsp;</p><p><em>Monitoring of treatment &ndash; laboratory tests</em></p><p>&nbsp;</p><p>There is no requirement for monitoring of NovoSeven therapy. Severity of bleeding condition and clinical response to NovoSeven administration must guide dosing requirements.</p><p>&nbsp;</p><p>After administration of rFVIIa, prothrombin time (PT) and activated partial thromboplastin time (aPTT) have been shown to shorten, however no correlation has been demonstrated between PT and aPTT and clinical efficacy of rFVIIa.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 or to mouse, hamster or bovine protein.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In pathological conditions in which tissue factor may be expressed more extensively than considered normal, there may be a risk of development of thrombotic events or induction of Disseminated Intravascular Coagulation (DIC) in association with NovoSeven treatment.</p><p>&nbsp;</p><p>Such situations may include patients with advanced atherosclerotic disease, crush injury, septicaemia or DIC. Because of the risk of thromboembolic complications, caution should be exercised when administering NovoSeven to patients with a history of coronary heart disease, to patients with liver disease, to <u>post-operative</u> patients, <u>to pregnant or peripartum women,</u> to neonates, or to patients at risk of thromboembolic <u>events</u> or <u>DIC</u>. In each of these situations, the potential benefit of treatment with NovoSeven should be weighed against the risk of these complications.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p><u>In severe postpartum haemorrhage and pregnancy, the clinical conditions (delivery, severe haemorrhage, transfusion, DIC, surgery/invasive procedures and coagulopathy) are known contributing factors to the thromboembolic risk; and in particular venous thromboembolic risk associated with the administration of NovoSeven (see section 4.8).</u></p><p>&nbsp;</p><p>As recombinant coagulation factor VIIa NovoSeven may contain trace amounts of mouse IgG, bovine IgG and other residual culture proteins (hamster and bovine serum proteins), the remote possibility exists that patients treated with the product may develop hypersensitivity to these proteins. In such cases treatment with antihistamines i.v. should be considered.</p><p>&nbsp;</p><p>If allergic or anaphylactic-type reactions occur, the administration should be discontinued immediately. In case of shock, standard medical treatment for shock should be implemented. Patients should be informed of the early signs of hypersensitivity reactions. If such symptoms occur, the patient should be advised to discontinue use of the product immediately and contact their physician.</p><p>&nbsp;</p><p>In case of severe bleeds the product should be administered in hospitals preferably specialised in treatment of haemophilia patients with coagulation factor VIII or IX inhibitors, or if not possible, in close collaboration with a physician specialised in haemophilia treatment.</p><p>&nbsp;</p><p>If bleeding is not kept under control hospital care is mandatory. Patients/carers should inform the physician/supervising hospital at the earliest possible opportunity about all usages of NovoSeven.</p><p>&nbsp;</p><p>Factor VII deficient patients should be monitored for prothrombin time and factor VII coagulant activity before and after administration of NovoSeven. In case the factor VIIa activity fails to reach the expected level or bleeding is not controlled after treatment with the recommended doses, antibody formation may be suspected and analysis for antibodies should be performed. Thrombosis has been reported in FVII deficient patients receiving NovoSeven during surgery but the risk of thrombosis in factor VII deficient patients treated with NovoSeven is unknown (see section 5.1).</p><p>&nbsp;</p><p><u>Sodium content</u></p><p><u>The medicinal product contains less than 1 mmol sodium (23&nbsp;mg) per injection, indicating that it is essentially &lsquo;sodium free&rsquo;.</u></p><p><u>&nbsp;</u></p><p><u>Traceability</u></p><p><u>In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.</u></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The risk of a potential interaction between NovoSeven and coagulation factor concentrates is unknown. Simultaneous use of prothrombin complex concentrates, activated or not, should be avoided.</p><p>&nbsp;</p><p>Antifibrinolytics have been reported to reduce blood loss in association with surgery in haemophilia patients, especially in orthopaedic surgery and surgery in regions rich in fibrinolytic activity, such as the oral cavity<u>. </u><u>Antifibrinolytics are also used to reduce blood loss in women with postpartum haemorrhage.</u> Experience with concomitant administration of antifibrinolytics and rFVIIa treatment is, however, limited.</p><p>&nbsp;</p><p>Based on a non-clinical study (see section 5.3) it is not recommended to combine rFVIIa and rFXIII. There are no clinical data available on interaction between rFVIIa and rFXIII.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>&nbsp;</p><p>As a precautionary measure, it is preferable to avoid use of NovoSeven during pregnancy. Data on a limited number of exposed pregnancies within approved indications indicate no adverse effects of rFVIIa on pregnancy or on the health of the foetus/new-born child. To date, no other relevant epidemiological data are available. Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development, parturition or postnatal development (see section 5.3).</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>&nbsp;</p><p>It is unknown whether rFVIIa is excreted in human breast milk. The excretion of rFVIIa in milk has not been studied in animals. A decision on whether to continue/discontinue breast-feeding or to continue/discontinue therapy with NovoSeven should be made taking into account the benefit of breast-feeding to the child and the benefit of NovoSeven therapy to the woman.</p><p>&nbsp;</p><p><u>Fertility</u></p><p><u>&nbsp;</u></p><p>Data from non-clinical studies as well as post-marketing data show no indication that rFVIIa has a harmful effect on male or female fertility.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effect on the ability to drive and use machines have been performed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>&nbsp;</p><p>The most frequently reported adverse drug reactions are decreased therapeutic response, pyrexia, rash, venous thromboembolic events, pruritus and urticaria. These reactions are reported as uncommon (&ge;&nbsp;1/1,000, &lt;&nbsp;1/100).</p><p>&nbsp;</p><p><u>Tabulated summary of adverse reactions</u></p><p>&nbsp;</p><p>Table 1 lists adverse reactions reported during clinical trials and from spontaneous (post-marketing) reports. Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness. Adverse drug reactions reported post-marketing only (i.e. not in clinical trials) are presented with a frequency of &lsquo;not known&rsquo;.</p><p>&nbsp;</p><p>Clinical trials conducted in 484 patients (including 4297 treatment episodes) with haemophilia A and B, acquired haemophilia, factor VII deficiency or Glanzmann&rsquo;s thrombasthenia have shown that adverse drug reactions are common (&ge;&nbsp;1/100 to &lt;&nbsp;1/10). As the total number of treatment episodes in clinical trials is below 10,000, the lowest possible frequency of adverse drug reactions that can be assigned is rare (<u>&ge;&nbsp;</u>1/10,000 to &lt;&nbsp;1/1,000).</p><p>&nbsp;</p><p>The most frequent adverse drug reactions are pyrexia and rash (uncommon: <u>&ge;</u>&nbsp;1/1,000 to &lt;&nbsp;1/100), and the most serious adverse drug reactions include venous thromboembolic events (uncommon: &ge;&nbsp;1/1,000 to &lt;&nbsp;1/100) and arterial thromboembolic events (rare: &ge;&nbsp;1/10,000 to &lt;&nbsp;1/1,000).</p><p>&nbsp;</p><p>The frequencies of both serious and non-serious adverse drug reactions are listed by system organ classes in the table below</p><p>&nbsp;</p><p><strong>Table 1 Adverse reactions from clinical trials and spontaneous (post-marketing) reports</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>MedDRA system organ class</p></td><td><p>Uncommon (&ge;1/1,000 to &lt;1/100)</p></td><td><p>Rare (&ge;1/10,000 to &lt;1/1,000)</p></td><td><p>Frequency Not Known</p></td></tr><tr><td><p>Blood and lymphatic system disorders</p></td><td><p>&nbsp;</p></td><td><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Disseminated intravascular coagulation (see section 4.4)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Related laboratory findings, including elevated levels of D-dimer and decreased levels of AT (see section 4.4)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Coagulopathy</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Gastrointestinal disorders</p></td><td><p>&nbsp;</p></td><td><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nausea</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>General disorders and administration site conditions</p></td><td><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Therapeutic response decreased*</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pyrexia</p></td><td><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Injection site reaction including injection site pain</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Immune system disorders</p></td><td><p>&nbsp;</p></td><td><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypersensitivity (see sections 4.3 and 4.4)</p></td><td><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anaphylactic reaction</p></td></tr><tr><td><p>Investigations</p></td><td><p>&nbsp;</p></td><td><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased fibrin degradation products</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increase of alanine aminotransferase, alkaline phosphatase, lactate dehydrogenase and prothrombin</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Nervous system disorders</p></td><td><p>&nbsp;</p></td><td><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Skin and subcutaneous tissue disorders</p></td><td><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rash (including allergic dermatitis and rash erythematous)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pruritus and urticaria</p></td><td><p>&nbsp;</p></td><td><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Flushing</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Angioedema</p></td></tr><tr><td><p>Vascular disorders</p></td><td><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Venous thromboembolic events (deep vein thrombosis, thrombosis at i.v. site, pulmonary embolism, thromboembolic events of the liver including portal vein thrombosis, renal vein thrombosis, thrombophlebitis, superficial thrombophlebitis and intestinal ischaemia)</p></td><td><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Arterial thromboembolic events (myocardial infarction, cerebral infarction, cerebral ischaemia, cerebral artery occlusion, cerebrovascular accident, renal artery thrombosis, peripheral ischaemia, peripheral arterial thrombosis and intestinal ischaemia)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Angina pectoris</p></td><td><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Intracardiac thrombus</p></td></tr></tbody></table><p>&nbsp;</p><p>* Lack of efficacy (therapeutic response decreased) has been reported. It is important that the dosage regimen of NovoSeven is compliant with the recommended dosage as stated in section 4.2.</p><p>&nbsp;</p><p><u>Description of selected adverse reactions</u></p><p><em>&nbsp;</em></p><p><em>Inhibitory antibody formation</em></p><p><em>&nbsp;</em></p><p>In post-marketing experience, there have been no reports of inhibitory antibodies against NovoSeven or FVII in patients with haemophilia A or B. Development of inhibitory antibodies to NovoSeven has been reported in a post-marketing observational registry of patients with congenital FVII deficiency.</p><p>&nbsp;</p><p>In clinical trials of patients with factor VII deficiency, formation of antibodies against NovoSeven and FVII is the only adverse drug reaction reported (frequency: common (&ge;&nbsp;1/100 to &lt;&nbsp;1/10)). In some cases, the antibodies showed inhibitory effect <em>in vitro</em>. Risk factors that may have contributed to antibody development including previous treatment with human plasma and/or plasma-derived factor VII, severe mutation of FVII gene, and overdose of NovoSeven, were present. Patients with factor VII deficiency treated with NovoSeven should be monitored for factor VII antibodies (see section 4.4).</p><p>&nbsp;</p><p><em>Thromboembolic events - arterial and venous</em></p><p>&nbsp;</p><p>When NovoSeven is administered to patients outside approved indications, arterial thromboembolic events are common (&ge;&nbsp;1/100 to &lt;&nbsp;1/10). A higher risk of arterial thromboembolic adverse events (see table: Vascular disorders) (5.6% in patients treated with NovoSeven versus 3.0% in placebo-treated patients) has been shown in a meta-analysis of pooled data from placebo-controlled trials conducted outside current approved indications in various clinical settings, each of these having distinct patient characteristics and hence different underlying risk profiles.</p><p>&nbsp;</p><p>Safety and efficacy of NovoSeven have not been established outside the approved indications and therefore NovoSeven should not be used.</p><p>&nbsp;</p><p>Thromboembolic events may lead to cardiac arrest.</p><p>&nbsp;</p><p><u>Other special populations</u></p><p>&nbsp;</p><p><em>Patients with acquired haemophilia</em></p><p>&nbsp;</p><p>Clinical trials conducted in 61&nbsp;patients with acquired haemophilia with a total of 100&nbsp;treatment episodes, showed that certain adverse drug reactions were reported more frequently (1% based on treatment episodes): Arterial thromboembolic events (cerebral artery occlusion, cerebrovascular accident), venous thromboembolic events (pulmonary embolism and deep vein thrombosis), angina pectoris, nausea, pyrexia, erythematous rash and investigation of increased levels of fibrin degradation products.</p><p>&nbsp;</p><p><em><u>Women with severe postpartum haemorrhage</u></em></p><p><u>&nbsp;</u></p><p><u>In an open-label randomised clinical trial, venous thromboembolic events were reported in 2&nbsp;of 51 patients treated with a single dose of NovoSeven (median dose 58</u><u>&nbsp;</u><u>&mu;g/kg) and none of 33 patients not treated with NovoSeven; no arterial thromboembolic events were reported in either group.</u></p><p><u>In 4 non-interventional studies, venous thromboembolic events were reported in 3 of 358 (0.8%) patients treated with NovoSeven (median dose range 63-105</u><u>&nbsp;</u><u>&micro;g/kg) and arterial thromboembolic events were reported in 1 (0.3%) patient treated with NovoSeven.</u></p><p><u>&nbsp;</u></p><p><u>For known contributing factors to thromboembolic risk associated with pregnancy and severe postpartum haemorrhage, see section 4.4.</u></p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p><u>&nbsp;</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the National Pharmacovigilance and Drug Safety Centre (NPC):</p><p>&nbsp;</p><p><strong>To report any side effect(s): </strong></p><table border="1" cellspacing="1" cellpadding="1"><tbody><tr><td><p>The National Pharmacovigilance Centre (NPC):</p><p>Fax: +966-11-205-7662</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Dose limiting toxicities of NovoSeven have not been investigated in clinical trials.</p><p>&nbsp;</p><p>Four cases of overdose have been reported in patients with haemophilia in 16&nbsp;years. The only complication reported in connection with an overdose was a slight transient increase in blood pressure in a 16&nbsp;year-old patient receiving 24&nbsp;mg rFVIIa instead of 5.5&nbsp;mg.</p><p>&nbsp;</p><p>No cases of overdose have been reported in patients with acquired haemophilia or Glanzmann&rsquo;s thrombasthenia.</p><p><u>&nbsp;</u></p><p>In patients with factor VII deficiency, where the recommended dose is 15&nbsp;&ndash;&nbsp;30&nbsp;&micro;g/kg rFVIIa, one episode of overdose has been associated with a thrombotic event (occipital stroke) in an elderly (&gt;&nbsp;80&nbsp;year) male patient treated with 10&nbsp;&ndash;&nbsp;20&nbsp;times the recommended dose. In addition, the development of antibodies against NovoSeven and FVII has been associated with overdose in one patient with factor VII deficiency.</p><p>&nbsp;</p><p>The dose schedule should not be intentionally increased above the recommended doses due to the absence of information on the additional risk that may be incurred.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Blood coagulation factors, ATC code: B02BD08</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>NovoSeven contains activated recombinant coagulation factor VII. The mechanism of action includes the binding of factor VIIa to exposed tissue factor. This complex activates factor IX into factor IXa and factor X into factor Xa, leading to the initial conversion of small amounts of prothrombin into thrombin. Thrombin leads to the activation of platelets and factors V and VIII at the site of injury and to the formation of the haemostatic plug by converting fibrinogen into fibrin. Pharmacological doses of NovoSeven activate factor X directly on the surface of activated platelets, localized to the site of injury, independently of tissue factor. This results in the conversion of prothrombin into large amounts of thrombin independently of tissue factor.</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p>The pharmacodynamic effect of factor VIIa gives rise to an increased local formation of factor Xa, thrombin and fibrin.</p><p>&nbsp;</p><p><u>The time to peak coagulant activity after administration of NovoSeven was approximately 10&nbsp;minutes in healthy subjects and patients with haemophilia. </u></p><p>&nbsp;</p><p>A theoretical risk for the development of systemic activation of the coagulation system in patients suffering from underlying diseases predisposing them to DIC cannot be totally excluded.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p>&nbsp;</p><p><em><u>Congenital FVII deficiency</u></em></p><p>&nbsp;</p><p>In an observational registry (F7HAEM-3578) covering subjects with congenital FVII deficiency, the median dose for long term prophylaxis against bleeding in 22 paediatric patients (below 12&nbsp;years of age) with Factor VII deficiency and a severe clinical phenotype was 30&nbsp;&micro;g/kg (range 17&nbsp;&micro;g/kg to 200&nbsp;&micro;g/kg; the dose most often used was 30&nbsp;&micro;g/kg in 10 patients) with a median dose frequency of 3 doses per week (range 1 to 7; the dose frequency most often reported was 3 per week in 13 patients).</p><p>&nbsp;</p><p>In the same registry 3 out of 91 surgical patients experienced thromboembolic events.</p><p>&nbsp;</p><p><em><u>Glanzmann&rsquo;s thrombasthenia</u></em></p><p>&nbsp;</p><p>An observational registry (F7HAEM-3521) covered 133&nbsp;subjects with Glanzmann&rsquo;s thrombasthenia treated with NovoSeven. The median dose per infusion for treatment of 333 bleeding episodes was 90&nbsp;&micro;g/kg (range 28 to 450&nbsp;&micro;g/kg). NovoSeven was used in 157&nbsp;surgical procedures, at a median dose of 92&nbsp;&micro;g/kg (up to 270&nbsp;&micro;g/kg). Treatment with NovoSeven, alone or in combination with antifibrinolytics and/or platelets, was defined as effective when bleeding was stopped for at least 6 hours. The efficacy rates were 81% and 82%, respectively, in patients with positive or negative refractoriness to platelet transfusions, and 77% and 85%, respectively, in patients testing positive or negative for antibodies to platelets. Positive status indicates at least one positive test at any admission.</p><p>&nbsp;</p><p><em><u>Severe postpartum haemorrhage</u></em></p><p><em><u>&nbsp;</u></em></p><p><u>The efficacy and safety of NovoSeven was assessed in 84 women with severe postpartum haemorrhage in a multicentre, open-label clinical trial. Patients were randomised either to treatment with a single dose of 60</u><u>&nbsp;</u><u>&micro;g/kg of NovoSeven (in addition to standard of care; N=42) or to reference therapy (standard of care alone; N=42), following failure of uterotonics (sulprostone). The treatment groups were well balanced in terms of demographic characteristics and postpartum haemorrhage treatment prior to randomisation. Fibrinogen and tranexamic acid were part of standard of care. Information on fibrinogen/tranexamic acid use was available from approximately 57% of patients in the NovoSeven group and 43% of patients in the reference group. Of these, about 40% of the patients in both groups received fibrinogen and/or tranexamic acid. Bleeding was considered to have stopped (i.e. treatment success) if the estimated blood flow decreased to less than 50</u><u>&nbsp;</u><u>ml per 10</u><u>&nbsp;</u><u>minutes within the 30</u><u>&nbsp;</u><u>minutes following randomisation. If the bleeding was uncontrolled or intractable, invasive procedures were considered.</u></p><p><u>&nbsp;</u></p><p><u>In the primary analysis, fewer women in the NovoSeven group (21 vs 35) had at least one embolisation and/or ligation procedure compared to the reference group, corresponding to a statistically significant 40% relative reduction in risk for the NovoSeven group compared to the reference group (relative risk = 0.60 (95% confidence interval: 0.43 &ndash; 0.84, p=0.0012)). </u></p><p><u>&nbsp;</u></p><p><u>In the reference group, 8 of the 42 patients received late NovoSeven as a compassionate treatment in an attempt to avoid salvage hysterectomy, which succeeded in 2 cases.</u></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Healthy subjects</em></p><p>&nbsp;</p><p><u>Distribution, elimination and linearity</u></p><p>Using the FVII clotting assay, the pharmacokinetics of rFVIIa were investigated in 35&nbsp;healthy Caucasian and Japanese subjects in a dose-escalation study. Subjects were stratified according to sex and ethnic group and dosed with 40, 80 and 160&nbsp;&micro;g rFVIIa per kg body weight (3&nbsp;doses each) and/or placebo. The pharmacokinetics were similar across sex and ethnic groups.</p><p>The mean steady state volume of distribution ranged from 130 to 165&nbsp;ml/kg, the mean values of clearance ranged from 33.3 to 37.2&nbsp;ml/h&times;kg.</p><p>The mean terminal half-life ranged from 3.9 to 6.0&nbsp;hours.</p><p>The pharmacokinetic profiles indicated dose proportionality.</p><p>&nbsp;</p><p><em>Haemophilia A and B with inhibitors</em></p><p>&nbsp;</p><p><u>Distribution, elimination and linearity</u></p><p>Using the FVIIa assay, the pharmacokinetic properties of rFVIIa were studied in 12&nbsp;paediatric (2 &ndash; 12&nbsp;years) and 5&nbsp;adult patients in non-bleeding state.</p><p>Mean volume of distribution at steady state was 196&nbsp;ml/kg in paediatric patients versus 159&nbsp;ml/kg in adults.</p><p>Mean clearance was approximately 50% higher in paediatric patients relative to adults (78 versus 53&nbsp;ml/h&times;kg), whereas the mean terminal half-life was determined to 2.3&nbsp;hours in both groups. Clearance appears related with age, therefore in younger patients clearance may be increased by more than 50%.</p><p>Dose proportionality was established in children for the investigated doses of 90 and 180&nbsp;&micro;g per kg body weight, which is in accordance with previous findings at lower doses (17.5 &ndash; 70&nbsp;&micro;g/kg rFVIIa).</p><p>&nbsp;</p><p><em>Factor VII deficiency</em></p><p><em>&nbsp;</em></p><p><u>Distribution and elimination</u></p><p>Single dose pharmacokinetics of rFVIIa, 15 and 30&nbsp;&mu;g per kg body weight, showed no significant difference between the two doses used with regard to dose-independent parameters:</p><p>Volume of distribution at steady state (280 &ndash; 290&nbsp;ml/kg), half-life (2.82 &ndash; 3.11&nbsp;h), total body clearance (70.8 &ndash; 79.1&nbsp;ml/h&times;kg) and mean residence time (3.75 &ndash; 3.80&nbsp;h).</p><p>The mean <em>in vivo</em> plasma recovery was approximately 20%.</p><p><em>&nbsp;</em></p><p><em>Glanzmann&rsquo;s thrombasthenia</em></p><p><strong>&nbsp;</strong></p><p>Pharmacokinetics of NovoSeven in patients with Glanzmann&rsquo;s thrombasthenia have not been investigated, but are expected to be similar to the pharmacokinetics in haemophilia A and B patients.</p><p>&nbsp;</p><p><em><u>Severe postpartum haemorrhage</u></em></p><p><u>&nbsp;</u></p><p><u>Pharmacokinetics of NovoSeven in patients with severe postpartum haemorrhage have not been investigated.</u></p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>All findings in the preclinical safety programme were related to the pharmacological effect of rFVIIa.</p><p>&nbsp;</p><p>A potential synergistic effect of combined treatment with rFXIII and rFVIIa in an advanced cardiovascular model in cynomolgus monkey resulted in exaggerated pharmacology (thrombosis and death) at a lower dose level than when administering the individual compounds.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Powder</u></p><p>Sodium chloride</p><p>Calcium chloride dihydrate</p><p>Glycylglycine</p><p>Polysorbate 80</p><p>Mannitol</p><p>Sucrose</p><p>Methionine</p><p>Hydrochloric acid (for pH-adjustment)</p><p>Sodium hydroxide (for pH-adjustment)</p><p>&nbsp;</p><p><u>Solvent</u></p><p>Histidine</p><p>Hydrochloric acid (for pH-adjustment)</p><p>Sodium hydroxide (for pH-adjustment)</p><p>Water for injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>NovoSeven must not be mixed with infusion solutions or be given in a drip.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The shelf life for the product packed for sale is 3 years when the product is stored below 25°C.

In vial
After reconstitution, chemical and physical stability has been demonstrated for 6 hours at 25°C and 24 hours at 5°C.
From a microbiological point of view, the product should be used immediately. If not used immediately, storage time and storage conditions prior to use are the responsibility of the user, and should not be longer than 24 hours at 2°C – 8°C, unless reconstitution has taken place in controlled and validated aseptic conditions. The reconstituted solution should be stored in the vial.

In syringe (50 ml polypropylene) in hospital settings only
Reconstitution must take place in controlled and validated aseptic conditions by adequately trained staff. Under these conditions, chemical and physical stability has been demonstrated for 24 hours at 25°C when stored in a 50 ml syringe (polypropylene). If not used immediately, the conditions prior to use are the responsibility of the user and the in-use storage time must not be longer than as stated above.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store powder and solvent below 25&deg;C.</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store powder and solvent protected from light.</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not freeze.</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For storage conditions of the reconstituted medicinal product, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The solvent of NovoSeven is provided in a pre-filled syringe. Not all presentations may be marketed.</p><p><u>&nbsp;</u></p><p><u>The NovoSeven 1&nbsp;mg (50&nbsp;KIU)/NovoSeven 2&nbsp;mg (100&nbsp;KIU) package contains </u></p><p>&nbsp;</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1&nbsp;vial (2&nbsp;ml) with white powder for solution for injection</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1&nbsp;pre-filled syringe (3&nbsp;ml) with solvent for reconstitution</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1&nbsp;plunger rod</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1&nbsp;vial adapter, with an integrated particle filter with a pore size of 25&nbsp;micrometer.</p><p>&nbsp;</p><p><u>The NovoSeven 5&nbsp;mg (250&nbsp;KIU)/NovoSeven 8&nbsp;mg (400&nbsp;KIU) package contains </u></p><p>&nbsp;</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1&nbsp;vial (12&nbsp;ml) with white powder for solution for injection</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1&nbsp;pre-filled syringe (10&nbsp;ml) with solvent for reconstitution</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1&nbsp;plunger rod</p><p>&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1&nbsp;vial adapter, with an integrated particle filter with a pore size of 25&nbsp;micrometer.</p><p>&nbsp;</p><p>Vial: Type I glass vial closed with a chlorobutyl rubber stopper, covered with an aluminium cap. The closed vial is equipped with a polypropylene tamper-evident snap-off cap.</p><p>&nbsp;</p><p>Pre-filled syringe: Type I glass barrel with a polypropylene backstop and bromobutyl rubber plunger. The syringe cap consists of bromobutyl rubber and polypropylene tamper evident seal.</p><p>&nbsp;</p><p>Plunger rod: made of polypropylene.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The solvent of NovoSeven is provided in a pre-filled syringe. Not all presentations may be marketed. Handling procedures are described below.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Powder in vial and solvent in pre-filled syringe:</u></p><p>&nbsp;</p><p>Always use an aseptic technique.</p><p>&nbsp;</p><p><em>Reconstitution</em></p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The NovoSeven powder vial and pre-filled syringe with solvent should be at room temperature at reconstitution. Remove the plastic cap from the vial. If the cap is loose or missing, do not use the vial. Wipe the rubber stopper on the vial with a sterile alcohol swab and allow it to dry for a few seconds before use. Do not touch the rubber stopper after wiping it.</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Remove the protective paper from the vial adapter. Do not take the vial adapter out of the protective cap. If the protective paper is not fully sealed or it is broken do not use the vial adapter. Turn over the protective cap, and snap the vial adapter onto the vial. Lightly squeeze the protective cap with the thumb and index finger. Remove the protective cap from the vial adapter.</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Screw the plunger rod clockwise into the plunger inside the pre-filled syringe until resistance is felt. Remove the syringe cap from the pre-filled syringe by bending it down until the perforation breaks. Do not touch the syringe tip under the syringe cap. If the syringe cap is loose or missing, do not use the pre-filled syringe.</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Screw the pre-filled syringe securely onto the vial adapter until resistance is felt. Hold the pre-filled syringe slightly tilted with the vial pointing downwards. Push the plunger rod to inject all the solvent into the vial. Keep the plunger rod pressed down and swirl the vial gently until all the powder is dissolved. Do not shake the vial as this will cause foaming.</p><p>&nbsp;</p><p>If a larger dose is needed, repeat the procedure with additional vials, pre-filled syringes and vial adapters.</p><p>&nbsp;</p><p>The NovoSeven reconstituted solution is colourless and should be inspected visually for particulate matter and discolouration prior to administration.</p><p>&nbsp;</p><p>It is recommended to use NovoSeven immediately after reconstitution. For storage conditions of the reconstituted medicinal product, see section 6.3.</p><p>&nbsp;</p><p><em>Administration</em></p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep the plunger rod pushed completely in. Turn the syringe with the vial upside down. Stop pushing the plunger rod and let it move back on its own while the reconstituted solution fills the syringe. Pull the plunger rod slightly downwards to draw the mixed solution into the syringe.<br />&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; While holding the vial upside down, tap the syringe gently to let any air bubbles rise to the top. Push the plunger rod slowly until all air bubbles are gone.</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If the entire dose is not required, use the scale on the syringe to see how much mixed solution is withdrawn.</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Unscrew the vial adapter with the vial.</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NovoSeven is now ready for injection. Locate a suitable site, and slowly inject NovoSeven into a vein over a period of 2 &ndash; 5&nbsp;minutes without removing the needle from the injection site.</p><p>&nbsp;</p><p>Safely dispose of the used materials. Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p><p>&nbsp;</p><p><u>Procedure for pooling of vials for hospital use only: </u></p><p>&nbsp;</p><p>During in vitro studies, the chemical and physical in-use stability has been demonstrated for 24&nbsp;hours at 25&deg;C in a 50&nbsp;ml syringe (polypropylene). Compatibility with the product was demonstrated for the system consisting of a 50&nbsp;ml syringe (polypropylene), a 2&nbsp;m infusion tube (polyethylene) and an in-line filter with a 5 micrometer pore size.</p><p>&nbsp;</p><p><em>Pooling of vials (hospital use only):</em></p><p><em>&nbsp;</em></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; All steps should be completed under controlled and validated aseptic conditions by adequately trained staff.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If not reconstituted, pooled or used as recommended the in-use times and conditions prior to use are the responsibility of the user.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ensure that a vial adapter is used.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reconstitute the product as described above under <em>Reconstitution.</em>&nbsp; Unscrew the empty syringe from the vial adapter and ensure that a vial adapter is attached to the vial containing reconstituted product.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Repeat the procedure with the appropriate number of additional vials, pre-filled syringes and vial adapters.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Draw approximately 5&nbsp;ml of sterile air into the 50&nbsp;ml syringe (polypropylene). Screw the syringe securely onto the vial adapter until resistance is felt. Hold the syringe slightly tilted with the vial pointing downwards. Push the plunger rod gently to inject a little air into the vial. Turn the syringe with the vial upside down and withdraw the contents of the vial into the syringe.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Repeat the above procedure with the remaining vials with reconstituted product, to obtain the desired volume in the syringe.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; An in-line filter with a 5 micrometer pore size must be ensured for administration. Ensure that the syringe, the infusion tube and the in-line filter are primed and free of air before administration.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The syringe with adequately reconstituted product is now ready for administration in a CE-marked infusion pump (accepting a 50&nbsp;ml syringe).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The infusion pump must only be operated by trained hospital personnel.</p><p><s>&nbsp;</s></p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Novo Nordisk A/S
Novo Allé
DK-2880 Bagsværd
Denmark
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                April-2022
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>